In this system, Cas9 and gRNA complexes of the CRISPR-Cas9 system generate double-strand breaks (DSBs) at target sequences of KRAS mutants, and the disrupted KRAS mutants inhibit tumor growth14,15. The gene discussed is KRAS; the disease is neoplasm.